In line with recent reports, SGLT2 inhibition suppressed glucose uptake, lactate release, ATP production and increased AMPK activation, opposing signaling pathways which contribute to metabolic reprogramming and tumor progression [34, 35, 63]. The gene discussed is SLC5A2; the disease is neoplasm.